- Global Pharma News & Resources

Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for induced pluripotent stem cell (iPSC)-derived macrophage cell therapies

London, UK and Toronto, Canada 7 November, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, CCRM, one of the leading companies developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and OmniaBio Inc., CCRM’s subsidiary, today announced a research collaboration to develop and scale up a manufacturing platform for Resolution’s off-the-shelf iPSC-derived macrophage cell therapies.

“An off-the-shelf product offering will reduce the complexity of the supply chain of our macrophage cell therapeutics. Allogeneic cell therapy will facilitate access to a greater number of treatment centres with potential to provide benefit to a larger group of patients with advanced liver disease. We are excited to partner with CCRM, a company with state-of-the-art facilities, deep expertise in manufacturing of iPSC-derived cell therapy and a track record of translating regenerative medicine-based technologies towards clinical development,” said Edward Hodgkin, CEO of Resolution. “The collaboration with CCRM and OmniaBio will enable us to build a scalable, GMP-compatible manufacturing platform for our off-the-shelf iPSC-derived macrophage cell therapies.”

“Resolution is a leader in the development of macrophage-based cell therapies,” said Michael May, President and CEO of CCRM. “We are delighted to be working with their team and look forward to leveraging our deep expertise in iPSC differentiation, process development and GMP manufacturing to enable Resolution Therapeutics’ efforts and accelerate the delivery of breakthrough medicines to patients in need.”

“The project with Resolution is being executed by OmniaBio, leveraging the technical skills within the teams at CCRM and OmniaBio,” explains Mitchel Sivilotti, CEO of OmniaBio Inc. “The launch of OmniaBio creates end-to-end support for companies like Resolution who need to move from process development to clinical-stage manufacturing and eventually commercial-scale manufacturing. OmniaBio has the expertise, infrastructure and a strong focus on cell and gene therapies to deliver impact on this project and eventually to patients.”

Editor Details

Related Links

Last Updated: 08-Nov-2022